Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity

European Heart Journal

Volumn 32, Issue 11, 2011, Pages 1369-1378

  Quercioli, Alessandra ^a   Pataky, Zoltan ^a   Vincenti, Gabriella ^a   Makoundou, Vincent ^a   Di Marzo, Vincenzo ^b   Montecucco, Fabrizio ^a   Carballo, Sebastian ^a   Thomas, Aurlien ^a   Staub, Christian ^a   Steffens, Sabine ^a   Seimbille, Yann ^a   Golay, Alain ^a   Ratib, Osman ^a   Harsch, Elisabetta ^a   MacH, Franois ^a   Schindler, Thomas H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

blood flow; circulation; coronary disease; endocannabinoids; endothelium; obesity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; AMMONIA N 13; ANANDAMIDE; DIPYRIDAMOLE; ENDOCANNABINOID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COLD PRESSOR TEST; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; VASODILATATION;

AGED; ARACHIDONIC ACIDS; BODY MASS INDEX; CASE-CONTROL STUDIES; CORONARY CIRCULATION; CORONARY DISEASE; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; OBESITY; POLYUNSATURATED ALKAMIDES; POSITRON-EMISSION TOMOGRAPHY;

EID: 79958109354     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr029     Document Type: Article

References (27)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
2. Fox KA, Despres JP, Richard AJ, Brette S, Deanfield JE. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91,246 ambulant patients in 27 European countries. Eur Heart J 2009;30:3055-3063.
3. Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, Sayre J, Dahlbom M, Licinio J, Schelbert HR. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006;47:1188-1195.
4. Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001;37:1523-1528.
5. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-1148.
6. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 2009;31:63-77.
7. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623-640.
8. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J 2010; 31:2984-2995.
9. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, Steffens S, Di Marzo V. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009;205:433-441.
10. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005;434:782-786. (Pubitemid 44739523)
11. Thomas A, Hopfgartner G, Giroud C, Staub C. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009;23:629-638.
12. DeGrado TR, Hanson MW, Turkington TG, Delong DM, Brezinski DA, Vallee JP, Hedlund LW, Zhang J, Cobb F, Sullivan MJ, Coleman RE. Estimation of myocardial blood flow for longitudinal studies with 13N-labeled ammonia and positron emission tomography. J Nucl Cardiol 1996;3(6 Pt 1):494-507.
13. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150-156.
14. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-1042. (Pubitemid 20104558)
15. Prior JO, Schindler TH, Facta AD, Hernandez-Pampaloni M, Campisi R, Dahlbom M, Schelbert HR. Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging 2007;34:20-27. (Pubitemid 44885550)
16. Siegrist PT, Gaemperli O, Koepfli P, Schepis T, Namdar M, Valenta I, Valenta I, Aiello F, Fleischmann S, Alkadhi H, Kaufmann PA. Repeatability of cold pressor test-induced flow increase assessed with H(2)(15)O and PET. J Nucl Med 2006; 47:1420-1426. (Pubitemid 47544926)
17. Schindler TH, Zhang XL, Prior JO, Cadenas J, Sayre J, Dahlbom M, Sayre J, Schelbert HR. Assessment of Intra- and Inter-observer Reproducibility of Rest and Cold-Pressor-Test Stimulated Myocardial Blood Flow with 13N-Ammonia and PET. Eur J Nucl Med Mol Imaging 2007;34:1178-1188. (Pubitemid 47290665)
18. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van Gaal L, Taskinen MR. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009;161:715-722.
19. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52:213-217.
20. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai SS, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843. (Pubitemid 41401077)
21. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180. (Pubitemid 44271774)
22. Motivala AA, Rose PA, Kim HM, Smith YR, Bartnik C, Brook RD, Muzik O, Duvernoy CS. Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal women. J Nucl Cardiol 2008;15:510-517.
23. Rubinshtein R, Yang EH, Rihal CS, Prasad A, Lennon RJ, Best PJ, Lerman LO, Lerman A. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J 2010;31:936-942.
24. Tiyerili V, Zimmer S, Jung S, Wassmann K, Naehle CP, Lutjohann D, Zimmer A, Nickenig G, Wassmann S. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol 2010;105:465-477.
25. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, Nakayama M, Kaikita K, Obata T, Takeya M, Ogawa H. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009;119:28-36.
26. Schindler TH, Campisi R, Dorsey D, Prior JO, Olschewski M, Sayre J, Schelbert HR. Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors. Eur Heart J 2009;30:978-986.
27. Schindler TH, Cadenas J, Facta AD, Li Y, Olschewski M, Sayre J, Goldin J, Schelbert HR. Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus. Eur Heart J 2009;30:3064-3073.